Duration of second complete remission compared with first complete remission in patients with acute myeloid leukemia
作者： S Lee , , MS Tallman , MM Oken , PA Cassileth
关键词:
摘要: The prognosis for patients with acute myeloid leukemia in first relapse is generally poor. ability to induce a second complete remission (CR) the same chemotherapy used initial induction therapy limited. Remission inversion rate, defined as achieving longer CR than response standard relapse, important assessing studies of novel or immunologic treatment strategies relapsed disease. One hundred and twenty-four entered on two Eastern Cooperative Oncology Group (ECOG) AML were analyzed determine rate. Twenty-two 124 (18%; 95% confidence interval 12-26%) experienced duration by at least 2 months. Inversion thus not rare event. frequency reported here establishes baseline upon which future disease need be defined.
nature.com
sci-hub.se 参考文章(31)
E Archimbaud, V Leblond, M Michallet, C Cordonnier, P Fenaux, P Travade, F Dreyfus, J Jaubert, Y Devaux, D Fiere, Intensive sequential chemotherapy with mitoxantrone and continuous infusion etoposide and cytarabine for previously treated acute myelogenous leukemia Blood. ,vol. 77, pp. 1894- 1900 ,(1991) , 10.1182/BLOOD.V77.9.1894.1894
J. M. Rowe, J. W. Andersen, J. J. Mazza, J. D. Hines, J. M. Bennett, P. A. Cassileth, E. Mansour, M. M. Oken, Treatment of Relapsed and Refractory AML with Mitoxantrone and Etoposide: A Study of the Eastern Cooperative Oncology Group Haematology and Blood Transfusion / Hämatologie und Bluttransfusion. pp. 235- 238 ,(1994) , 10.1007/978-3-642-78350-0_40
A Heinecke, C M Sauerland, W R Martin, T Büchner, W Hiddemann, Definition of refractoriness against conventional chemotherapy in acute myeloid leukemia: a proposal based on the results of retreatment by thioguanine, cytosine arabinoside, and daunorubicin (TAD 9) in 150 patients with relapse after standardized first line therapy. Leukemia. ,vol. 4, pp. 184- 188 ,(1990)
E Estey, Treatment of refractory AML. Leukemia. ,vol. 10, pp. 932- 936 ,(1996)
CM Higuchi, JA Thompson, FB Petersen, CD Buckner, A Fefer, Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood. ,vol. 77, pp. 2561- 2568 ,(1991) , 10.1182/BLOOD.V77.12.2561.2561
J Yates, O Glidewell, P Wiernik, MR Cooper, D Steinberg, H Dosik, R Levy, C Hoagland, P Henry, A Gottlieb, C Cornell, J Berenberg, JL Hutchison, P Raich, N Nissen, RR Ellison, R Frelick, GW James, G Falkson, RT Silver, F Haurani, M Green, E Henderson, L Leone, JF Holland, Cytosine arabinoside with daunorubicin or adriamycin for therapy of acute myelocytic leukemia: a CALGB study Blood. ,vol. 60, pp. 454- 462 ,(1982) , 10.1182/BLOOD.V60.2.454.454
BA Peterson, CD Bloomfield, Long-term disease-free survival in acute nonlymphocytic leukemia Blood. ,vol. 57, pp. 1144- 1147 ,(1981) , 10.1182/BLOOD.V57.6.1144.1144
GL Phillips, DE Reece, JD Shepherd, MJ Barnett, RA Brown, DA Frei-Lahr, HG Klingemann, BJ Bolwell, JJ Spinelli, RH Herzig, High-dose cytarabine and daunorubicin induction and postremission chemotherapy for the treatment of acute myelogenous leukemia in adults Blood. ,vol. 77, pp. 1429- 1435 ,(1991) , 10.1182/BLOOD.V77.7.1429.BLOODJOURNAL7771429
PH Wiernik, PL Banks, DC Jr Case, ZA Arlin, PO Periman, MB Todd, PS Ritch, RE Enck, AB Weitberg, Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia Blood. ,vol. 79, pp. 313- 319 ,(1992) , 10.1182/BLOOD.V79.2.313.313
M J Keating, H Kantarjian, T L Smith, E Estey, R Walters, B Andersson, M Beran, K B McCredie, E J Freireich, Response to salvage therapy and survival after relapse in acute myelogenous leukemia. Journal of Clinical Oncology. ,vol. 7, pp. 1071- 1080 ,(1989) , 10.1200/JCO.1989.7.8.1071